Research and Development and License Agreements (Details) £ in Thousands			1 Months Ended					3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 09, 2022 USD ($)	Jun. 06, 2017 GBP (£)	Mar. 31, 2022 USD ($)	Sep. 17, 2021 USD ($)	Jul. 31, 2021 USD ($)	Jun. 30, 2021 USD ($)	Jun. 29, 2021 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)	Apr. 21, 2022 USD ($)	Jan. 31, 2022 USD ($)	Sep. 30, 2021 USD ($)
Research and Development and License Agreements [Line Items]
Description of lipocure agreement										Under the Lipocure Agreement, the Company was required to pay an upfront fee upon signing of $150,000 and is required to make future milestone and royalty payments to Lipocure. The Company is obligated to make aggregate milestone payments of up to $19.8 million upon the achievement of specified development and commercial milestones. Lipocure met the development milestone of $300,000 in the third quarter of 2023 for successfully completing a formulation for the Licensed Product. The Company paid $150,000 in the third quarter of 2023 and will pay the balance in the fourth quarter of 2023. Royalty payments must be paid in an amount equal to a single digit to low double-digit percentage of annual net sales of royalty qualifying products, subject to certain adjustments. Royalties shall be payable during the period of time, on a country-by-country basis, commencing on the first commercial sale and ending upon the expiration of the last-to-expire patent claim on the licensed product, which is set to expire on July 24, 2030.
Research and development expenses								$ 1,495,619	$ 2,805,103	$ 4,022,020	$ 9,404,980
Service fees						$ 337,500
Description of agreement rendering of research services										In consideration for the research services, the Company agreed to pay research service fees of $1,286,000 in four equal quarterly installments ($321,500 per calendar quarter), as well as reasonable pass-through expenses. All services to be provided under the January 2023 Lipocure Research Agreement initiated on January 1, 2023, and are anticipated to be completed towards the end 2023.
MedPharm License Agreement [Member]
Research and Development and License Agreements [Line Items]
Aggregate milestone payments | £		£ 1,150
Nanomerics Collaboration Agreement [Member]
Research and Development and License Agreements [Line Items]
Aggregate milestone payments										$ 103,000,000
Amended Nanomerics License Agreement [Member]
Research and Development and License Agreements [Line Items]
Aggregate milestone payments	$ 112,500,000
Milestone payments	5,500,000
Additional aggregate milestone payments	$ 999,999
Nonrefundable fee of research and development expenses			$ 1,500,000
Amended Nanomerics License Agreement [Member] | Minimum [Member]
Research and Development and License Agreements [Line Items]
Profit share arrangement percentage	30.00%
Percentage of royalties	5.00%
Amended Nanomerics License Agreement [Member] | Maximum [Member]
Research and Development and License Agreements [Line Items]
Profit share arrangement percentage	40.00%
Percentage of royalties	15.00%
Nanomerics License Agreement [Member]
Research and Development and License Agreements [Line Items]
Aggregate milestone payments				$ 41,000,000
Amount paid for milestone payment				$ 200,000									$ 500,000
Nanomerics License Agreement [Member] | Minimum [Member]
Research and Development and License Agreements [Line Items]
Royalty payments percentage				5.00%
Nanomerics License Agreement [Member] | Maximum [Member]
Research and Development and License Agreements [Line Items]
Royalty payments percentage				15.00%
Yissum Research Agreement [Member]
Research and Development and License Agreements [Line Items]
Research and development expenses								81,500	56,250
Description of yissum research agreement										the Company entered into an Agreement for Rendering of Research Services with Yissum (the “January 2023 Yissum Research Agreement”) on substantially similar terms and conditions as detailed above under the June 2021 Yissum Research Agreement. Under the January 2023 Yissum Research Agreement, the Company shall provide funding for research and development studies to be performed by researchers at Hebrew University related to the optimization of the Liposomal Bupivacaine formulation (Probudur) and to increase stability for manufacturing purposes. The Company may terminate the agreement at any time and shall be only responsible to pay Yissum for work performed through the date of termination. In consideration for the research services, the Company agreed to pay research service fees of $326,000 in four equal quarterly installments ($81,500 per calendar quarter). All services to be provided under the January 2023 Yissum Research Agreement initiated in January 1, 2023, and are anticipated to be completed towards the end 2023.
Research and development expense of additional payment										$ 244,500	187,500
Lipocure Research Agreement [Member]
Research and Development and License Agreements [Line Items]
Research and development expenses								$ 488,000	$ 270,000	1,130,000	900,000
Research and development expense of additional payment												$ 270,000
Research service fees					$ 400,000		$ 200,000
Research service fees paid in quarterly payments														$ 270,000	$ 270,000
Lipocure payment										250,000
LipocureRx, Ltd. [Member]
Research and Development and License Agreements [Line Items]
Research and development expenses										$ 300,000	$ 0